Oral Administration of Chitosan Attenuates Bleomycin-induced Pulmonary Fibrosis in Rats
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, You-Seok | - |
dc.contributor.author | Li, Qiang | - |
dc.contributor.author | Youn, Hwa-Young | - |
dc.contributor.author | Kim, Dae Young | - |
dc.date.available | 2020-02-27T02:22:38Z | - |
dc.date.created | 2020-02-04 | - |
dc.date.issued | 2019-09 | - |
dc.identifier.issn | 0258-851X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/1048 | - |
dc.description.abstract | Background/Aim: Idiopathic pulmonary fibrosis (PF) is a fatal disorder of unknown aetiology with limited treatment options. Chitosan has antibacterial, antifungal, antioxidant, antitumour, and anti-inflammatory effects. This study aimed to investigate the effects of chitosan administration on bleomycin (BLM)-induced PF in rats. Materials and Methods: A PF rat model was established by endotracheal instillation of 5 mg/kg BLM; then, chitosan was administered in drinking water for 3 weeks. Histology, cell counts, and cytokine responses in the bronchoalveolar lavage fluid (BALF) and weight measurements (body and lung) were analyzed to assess its therapeutic effects. Results: Chitosan administration tended to reduce transforming growth factor (TGF)-beta 1 and interferon (IFN)-gamma levels in BALF, and histopathological examination confirmed that chitosan attenuated the degree of inflammation and fibrosis in the lung. Conclusion: This study revealed that oral chitosan exhibits potential antifibrotic effects, as measured by decreased proinflammatory cytokine levels and histological evaluation, in a BLM-induced PF rat model. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | INT INST ANTICANCER RESEARCH | - |
dc.relation.isPartOf | IN VIVO | - |
dc.subject | LUNG FIBROSIS | - |
dc.subject | ACTIVATION | - |
dc.title | Oral Administration of Chitosan Attenuates Bleomycin-induced Pulmonary Fibrosis in Rats | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000484008000009 | - |
dc.identifier.doi | 10.21873/invivo.11624 | - |
dc.identifier.bibliographicCitation | IN VIVO, v.33, no.5, pp.1455 - 1461 | - |
dc.identifier.scopusid | 2-s2.0-85071758374 | - |
dc.citation.endPage | 1461 | - |
dc.citation.startPage | 1455 | - |
dc.citation.title | IN VIVO | - |
dc.citation.volume | 33 | - |
dc.citation.number | 5 | - |
dc.contributor.affiliatedAuthor | Kim, Dae Young | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Bleomycin | - |
dc.subject.keywordAuthor | chitosan | - |
dc.subject.keywordAuthor | oral administration | - |
dc.subject.keywordAuthor | pulmonary fibrosis | - |
dc.subject.keywordPlus | LUNG FIBROSIS | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.